PANCREATIC ACINAR CELL CARCINOMA
Clinical trials for PANCREATIC ACINAR CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new PANCREATIC ACINAR CELL CARCINOMA trials appear
Sign up with your email to follow new studies for PANCREATIC ACINAR CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immunotherapy duo takes on 50+ rare cancers in major trial
Disease control OngoingThis phase 2 trial tests a combination of two immunotherapy drugs (nivolumab and ipilimumab) in over 800 people with more than 50 types of rare cancers. The goal is to see if this treatment can shrink tumors by helping the immune system attack cancer cells. The study is for patie…
Matched conditions: PANCREATIC ACINAR CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New Three-Drug cocktail targets genetic weakness in tough pancreatic cancer
Disease control OngoingThis study compares a three-drug chemotherapy combination (nab-paclitaxel, gemcitabine, plus cisplatin) against the standard two-drug combination (nab-paclitaxel plus gemcitabine) for people with metastatic pancreatic cancer that has spread to other parts of the body. Participant…
Matched conditions: PANCREATIC ACINAR CELL CARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New vaccine approach targets Hard-to-Treat pancreatic cancer
Disease control OngoingThis early-phase study tested a vaccine therapy given directly into the tumor along with a growth factor to boost the immune system in 18 people with advanced pancreatic cancer that could not be removed by surgery. The main goal was to find the safest dose and check for side effe…
Matched conditions: PANCREATIC ACINAR CELL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
Experimental drug cocktail targets Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests a combination of two targeted drugs (vismodegib and erlotinib) with or without a standard chemotherapy drug (gemcitabine) in people with advanced pancreatic cancer or other solid tumors that cannot be surgically removed. The main goal is to find the s…
Matched conditions: PANCREATIC ACINAR CELL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 08, 2026 12:04 UTC